CARA News 13.38 Cara Therapeutics Inc. (CARA)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cara Therapeutics Inc. (CARA) 13.38 $CARA

Healthcare Companies Report Transactions, Appeals, New Research Findings and Stock Movements - Analyst Notes on Johnson & Johnson, Teva, Celgene, Cara Therapeutics, and OncoMed Pharmaceuticals
PR Newswire - Thu Apr 03, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Johnson & Johnson (NYSE: JNJ), Teva Pharmaceutical Industries Limited (NYSE: TEVA), Celgene Corporation (NASDAQ: CELG), Cara Therapeutics Inc. (NASDAQ: CARA), and OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Cara Therapeutics to Webcast Presentation at 13th Annual Needham Healthcare Conference
GlobeNewswire - Wed Apr 02, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that Dr. Derek Chalmers, President and CEO, will present a company overview at the 13 Annual Needham Healthcare Conference on Wednesday, April 9, 2014 at 9:20 a.m. ET in New York City.

Cara Therapeutics Inc. (CARA) Worth Watching: Stock Surges 12.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:57AM CDT
Cara Therapeutics Inc. was a big mover last session, as the company saw its shares rise nearly 13% on the day.

Cara Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
GlobeNewswire - Thu Mar 27, 3:12PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced financial results for the fourth quarter and full year ended December 31, 2013.

Cara Therapeutics to Announce Fourth Quarter and Full Year 2013 Financial Results on March 27, 2014
GlobeNewswire - Thu Mar 20, 3:01PM CDT
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, announced today that the Company will host a conference call and live audio webcast on Thursday, March 27, 2014, at 4:30 p.m. ET to report fourth quarter and full year 2013 financial results and provide a corporate update.

'Mad Money' Lightning Round: No Fan of Lionsgate
at The Street - Thu Mar 13, 5:00AM CDT
Cramer is cautious on Cara Therapeutics but thinks DaVita is a terrific health care play.

Jim Cramer's 'Mad Money' Recap: Lost in the Rotation
at The Street - Wed Mar 12, 7:07PM CDT
The market's gyrations may seem maddening to those with longer-term views so those investors need to stay diversified, Cramer says.

New Appointments, Contract Extensions, Share Price Movements, Conference Schedules, and Closing of Public Offerings - Analyst Notes on Ariad, Novavax, Fonar, bluebird, and Cara
PR Newswire - Wed Mar 05, 6:24AM CST
Today, Analysts Review released its analysts' notes regarding Ariad Pharmaceuticals Inc. (NASDAQ: ARIA), Novavax, Inc. (NASDAQ: NVAX), Fonar Corp. (NASDAQ: FONR), bluebird bio, Inc. (NASDAQ: BLUE), and Cara Therapeutics Inc. (NASDAQ: CARA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Cara Therapeutics (CARA) Zooms: Stock Up 12.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 28, 8:39AM CST
Cara Therapeutics Inc. was a big mover last session, as its shares surged over 12% on the day.

Cara Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Over-Allotment Option
GlobeNewswire - Wed Feb 05, 3:01PM CST
Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the closing of its initial public offering of 5,750,000 shares of common stock at a public offering price of $11.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 750,000 additional shares of common stock at the same price to cover over-allotments.

IPO roundup: 6 companies go public Friday
By The Associated Press - AP - Fri Jan 31, 5:32PM CST
Six companies made their stock market debuts Friday as the IPO market revs up in 2014. Last year the market for initial public offerings boomed as stock markets rose, with major debuts from hotel owner Hilton Worldwide Holdings Inc., which raised $2.35 billion, and online messaging service Twitter Inc., which raised $2.1 billion.

Cara Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire - Fri Jan 31, 6:00AM CST
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain by selectively targeting kappa opioid receptors, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $11.00 per share, before underwriting discounts. In addition, Cara Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock at the same price to cover over-allotments, if any. The shares are scheduled to begin trading on the NASDAQ Global Market on January 31, 2014 under the ticker symbol "CARA." The offering is expected to close on February 5, 2014, subject to customary closing conditions.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vertiv's SmartIT: The New AI Infrastructure Game-Changer

Updated Category News Views 80

Taking AI Infrastructure Up a Notch Vertiv Holdings Co. (NYSE: VRT) is charging ahead with a solution that's bound to rattle the cages of status quo infrastructure deployments. Say hello to Vertiv™ SmartIT, a finely-tuned piece of kit that's pre-engineered to ease up the often painful process of high-density AI deployments across various environments—from homey...

Continue Reading
Custom Concrete: Crafting the Perfect Poolside Paradise

Updated Category News Views 34

Concrete: The Unsung Hero of Your Pool's Success You know, everyone always raves about that sparkling pool, but let's be real—it's the concrete holding the whole gig together. James White from White's Pools in Loganville, GA, drops some knowledge in a recent HelloNation piece about the unsung hero of backyard oases: custom concrete. Yeah, it's not sexy, but when you're...

Continue Reading
Better Home & Finance Faces 28.5% Stock Plunge, Lawsuit

Updated Category News Views 108

The Sudden Dive in Better Home's Stock Imagine cruising down the highway with the wind in your hair and suddenly slamming into a pothole. That's the kind of jarring experience Better Home & Finance Holding Company (NASDAQ: BETR) investors felt when the stock took a nosedive, diving a hefty 28.5%. Back on May 7, 2026, the company released financial figures that flipped the...

Continue Reading
Cumberland Pharmaceuticals Eyes NDA for Ifetroban in DMD

Updated Category News Views 44

Rolling the Dice with Ifetroban There's a buzz in the air around Cumberland Pharmaceuticals as they gear up to tackle one of medicine's stubborn giants, Duchenne muscular dystrophy (DMD). They plan to file a New Drug Application (NDA) with the FDA for ifetroban, aiming to treat the cardiomyopathy plaguing many DMD sufferers. Folks who’ve watched Cumberland (NASDAQ:CPIX)...

Continue Reading
Federal Law Shifts Landscape for Manufactured Housing

Updated Category News Views 93

Federal Act Aims to Boost Manufactured Homes Price tags on homes need a reality check, and for a long time, manufactured housing has been in the corner looking for a chance to throw its hat in the ring. Enter the 21st Century ROAD to Housing Act, aiming to finally unlock the potential sitting in our backyards when it comes to these factory-built options. We're talking...

Continue Reading
Gildan Activewear Faces Major Class Action Lawsuit

Updated Category News Views 151

Investors Turn Against Gildan Activewear Ever see a freight train barreling down the track? That's what it feels like when a class action lawsuit rears its head against a behemoth like Gildan Activewear Inc. (NYSE: GIL). After years of allegedly pulling the wool over investors' eyes, those same investors are now being called to muster—their chance to lead a charge of...

Continue Reading
Temu Partners with Recyclia to Drive EPR Compliance Boost

Updated Category News Views 182

Temu and Recyclia: Building a Sustainable Marketplace Get this: Temu, the e-commerce giant you've heard trumpeting about affordable goods like some digital bazaar, is diving deeper into sustainability waters with a partner that knows a thing or two about waste. This time, they've linked up with Recyclia over in Spain. The duo's focus? Helping marketplace sellers meet the...

Continue Reading
3TREES Debuts Green Coatings to East African Market

Updated Category News Views 0

3TREES Rocks East Africa's Construction Scene Nairobi's got a spark this week, and it's radiating straight from 3TREES' corner at the Big 5 Construct Kenya. With the Sarit Expo Centre buzzing from October 21, 2026, this Chinese company didn't just show up—they made one hell of an entrance. Presenting eco-friendly coating solutions, they pushed the 'Create Healthy Life'...

Continue Reading
Superteam Wheels Rides Into Spain with RACEIT Deal

Updated Category News Views 151

Rolling Out the Red Carpet for Spanish Cyclists Think of it as the pedal-powered bridge from wherever Superteam Wheels calls home to the sunny streets of Spain. If you're in the cycling game, this new partnership between Superteam Wheels and COMERTECH RACEIT, S.L., better known as RACEIT, is drawing a line in the sand—or perhaps on the asphalt—across Europe. Starting...

Continue Reading
Sintilimab Poised for New Milestone in Melanoma Fight

Updated Category News Views 188

An Opening Shot: NMPA's Decision Window Well, here's the latest chapter in the saga of battling advanced melanoma with some real gritty numbers behind it. Innovent Biologics has thrown its hat back in the ring with news that the China National Medical Products Administration (NMPA) has embraced a new indication application for their drug sintilimab. They're teaming it up...

Continue Reading

Top 5 Most Recently Viewed Articles

Alphyn Biologics: Zabalafin Hydrogel Hits Phase 2—What's Next?

Updated Category News Views 167

Alphyn Biologics launched its Phase 2 clinical trial for Zabalafin Hydrogel (ZH) on February 18, 2026. This is no small fry; we’re talking about tackling molluscum contagiosum (MC), a viral skin infection that plagues kids. Parents are already feeling the pinch of managing this highly contagious condition that spreads like wildfire and leaves unsightly bumps on their...

Continue Reading
Limited Time 50% Off Subscription: Empowering Technology Insights

Updated Category News Views 177

Unlock Your Access to Essential Technology Insights For those passionate about understanding the rapidly evolving technological landscape, MIT Technology Review presents an exciting opportunity. With their new, limited-time offer of 50% off an annual subscription, readers are invited to delve deep into the stories and innovations shaping our lives. What You Will Discover...

Continue Reading
Hilton Hotel Workers Demand Fair Wages and Work Conditions

Updated Category News Views 289

Hilton Hotel Workers Stage Strikes in Seattle In a significant move for labor rights, more than a hundred workers at Hilton hotels in Seattle have taken to the streets, demanding better wages and improved working conditions. The Unite Here union, which represents hospitality workers, organized the strike to address several pressing issues affecting its members. Reasons...

Continue Reading
Nüspace Marks a Year of Success with Special Anniversary Event

Updated Category News Views 56

Celebrating Nüspace's Successful Anniversary at Quartier DIX30 Nüspace, a prominent Canadian retailer in contemporary furniture, recently celebrated the first anniversary of its store located at Quartier DIX30. This notable event is a wonderful opportunity not only to commemorate a successful year but also to engage with valued customers and connect with the design...

Continue Reading
Thermal Containment Market Growth Projections and Trends

Updated Category News Views 106

Understanding the Thermal Containment Market Growth The global thermal containment market is predicted to see significant growth, expected to climb from USD 6.6 billion to USD 14.8 billion by 2033. This growth translates into a notable CAGR of 9.4%. The rise in demand for efficient cooling systems is driving this market expansion worldwide. What is Thermal Containment?...

Continue Reading